Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.

Registrati

Quotazioni in diretta

CYCC Cyclacel Pharmaceuticals Inc

0,31

0,0024 (0,78%)

Ultimo aggiornamento: 16:26:15

Dati in Delay di 15 minuti

$8 Million Private Placement Announcement Sends Biotech Flying

Usually when a publicly traded company announces some sort of equity offering, it can be viewed as a dilutive event, thus having a negative effect on the company’s price per...

To read the full story on AllPennyStocks.com, click here.

Grafico Azioni Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Storico
Da Feb 2025 a Mar 2025

Clicca qui per i Grafici di Cyclacel Pharmaceuticals

Grafico Azioni Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Storico
Da Mar 2024 a Mar 2025

Clicca qui per i Grafici di Cyclacel Pharmaceuticals

Notizie Cyclacel Pharmaceuticals Inc - CYCC

Cyclacel Pharmaceuticals Announces Closing of a Change of Control Transaction and Appointment of New Executive Leadership
Giovedì 27 Febbraio 2025 (2 settimane fa) • GlobeNewswire Inc.

Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar
Venerdì 3 Gennaio 2025 (2 mesi fa) • GlobeNewswire Inc.

Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs
Giovedì 5 Dicembre 2024 (3 mesi fa) • GlobeNewswire Inc.

Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds
Giovedì 14 Novembre 2024 (4 mesi fa) • GlobeNewswire Inc.

Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds
Mercoledì 13 Novembre 2024 (4 mesi fa) • GlobeNewswire Inc.

Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
Martedì 12 Novembre 2024 (4 mesi fa) • GlobeNewswire Inc.

Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule
Giovedì 24 Ottobre 2024 (5 mesi fa) • GlobeNewswire Inc.

Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
Mercoledì 23 Ottobre 2024 (5 mesi fa) • GlobeNewswire Inc.

Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium
Mercoledì 9 Ottobre 2024 (5 mesi fa) • GlobeNewswire Inc.

Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study
Mercoledì 25 Settembre 2024 (5 mesi fa) • GlobeNewswire Inc.

Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference
Mercoledì 4 Settembre 2024 (6 mesi fa) • GlobeNewswire Inc.

Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter
Martedì 3 Settembre 2024 (6 mesi fa) • GlobeNewswire Inc.

Più Cyclacel Pharmaceuticals Inc Articoli Notizie

Intesa Sanpaolo

Banca Monte Dei Paschi D...

ST Microelectronics

Delayed Upgrade Clock

Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US ADVFN Korea